Mo1217 Effects of Continued Vedolizumab Therapy for Crohn's Disease in Week 6 Induction Therapy Nonresponders
William J. Sandborn(University of San Diego), Irving H. Fox(Takeda (United States)), Jing Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Asit Parikh, Walter Reinisch(Medical University of Vienna), Michael Smyth, Brian G. Feagan(Western University)
Cited by 4
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k